Zenflow is a medical device company developing innovative therapies for the treatment of benign prostatic hyperplasia (BPH).
zenflow.comLinkedInSouth San Francisco, Calif.Medtech
16 sources · checked 1 time, last 45d ago
The article also says Zenflow secured venture debt financing but gives no debt amount. The announcement date is the Monday referenced in the October 6, 2026 article.
Published by hand (globenewswire.com): "Zenflow, Inc., developer of the Zenflow Spring® System, announced the close of an oversubscribed $52 million Series D financing round.": thin histories (K): hand-checked; the company's GlobeNewswire release of Oct 5 2026 announces this Series D, so it is not a late re-report of a 2024 round (the ledger's 2024-11-19 date is wrong); restores the row's published state
3 sources
The page is published November 19, but the release dateline states November 18 and says “today”; the dateline fixes the announcement date.
2 sources
The source identifies South San Francisco in the dateline, but does not state that it is Zenflow’s headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D | $52M $52M financing total | 2026-10-05 | Cook Medical | No recent discussion |
16 sources · checked 1 time, last 45d ago [ VERIFIED · CORRECTED ] read against 1 of 16 sources
The article also says Zenflow secured venture debt financing but gives no debt amount. The announcement date is the Monday referenced in the October 6, 2026 article. Published by hand (globenewswire.com): "Zenflow, Inc., developer of the Zenflow Spring® System, announced the close of an oversubscribed $52 million Series D financing round.": thin histories (K): hand-checked; the company's GlobeNewswire release of Oct 5 2026 announces this Series D, so it is not a late re-report of a 2024 round (the ledger's 2024-11-19 date is wrong); restores the row's published state | ||||
Zenflow builds minimally invasive medical devices—led by its reversible Zenflow Spring implant—to treat urinary symptoms caused by an enlarged prostate for men with benign prostatic hyperplasia.
BPH affects more than 30 million U.S. men, while the company says existing drug and surgical choices can bring limited relief, side effects, or procedural trauma; Zenflow’s Spring is positioned as a minimally invasive, reversible office treatment that avoids tissue removal and post-procedure catheterization. The latest $52 million Series D led by Cook Medical, together with an exclusive U.S. distribution agreement, is intended to accelerate commercialization after FDA approval, while the BREEZE study reported a 37% mean symptom-score improvement at 12 months and 99% of men avoiding catheterization.
Checked against 10 sources on Oct 5
| Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $24M | 2024-11-18 | not stated | No recent discussion |
3 sources [ VERIFIED · CORRECTED ] read against 1 of 3 sources The page is published November 19, but the release dateline states November 18 and says “today”; the dateline fixes the announcement date. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]3 pages read: globenewswire.com, finsmes.com, citybiz.co·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 3 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series B Series B financing round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $24M | 2021-06-02 | Invus Opportunities | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 1 of 2 sources The source identifies South San Francisco in the dateline, but does not state that it is Zenflow’s headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: globenewswire.com, massdevice.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: National Institutes of Health (NIH), National Science Foundation (NSF), Y Combinator, StartX, Rosenman Institute at QB3